Eli Lilly and WuXi Biologics-backed biologics developer Inhibrx floated at the midpoint of its range having previously raised $135m in debt and equity financing.
Inhibrx, a US-based biologic drug developer backed by pharmaceutical firm Eli Lilly and medical development services firm WuXi Biologics, floated yesterday in a $119m initial public offering
The offering consisted of 7 million shares, increased from 6 million, which were priced at $17.00 each, at the midpoint of the IPO’s $16 to $18 range. The company listed on the Nasdaq Global Market yesterday and its shares closed at $20.63, giving it a $757m market capitalisation.
Founded in 2010, Inhibrx…
